title: Association of HLA phenotypes of end-stage renal disease patients preparing for first transplantation with anti-HLA antibody status.
abstract: Patients with pre-transplantation high levels of panel reactive antibody (PRA) have an increased risk of graft failure, and renal transplantation in sensitized patients remains a highly significant challenge worldwide. The influence of anti-human leukocyte antigen (HLA) antibodies on the development of rejection episodes depends on patient-specific clinical factors and differs from patient to patient. The HLA typing of the recipient might influence the development of anti-HLA antibodies. Some HLA antigens appear to be more immunogenic than others. The aim of this study is to demonstrate the distribution of HLA phenotypes in PRA-positive and PRA-negative end-stage renal disease (ESRD) patients on the basis of having sensitizing events or not. Our study included 642 (mean age: 41.54; female/male: 310/332) ESRD patients preparing for the first transplantation and who are on the cadaveric kidney transplantation waiting list of Istanbul Medical Faculty in 2008-2009. Class I HLA-A,B typing was performed by complement-dependent cytotoxicity (CDC) method, whereas class II HLA-DRB1 typing was performed by low-resolution polymerase chain reaction (PCR)-sequence-specific primer (SSP). All serum samples were screened for the presence of IgG type of anti-HLA class I- and II-specific antibodies by enzyme-linked-immunosorbent assay (ELISA). PRA-negative group consisted of 558 (86.9%) and PRA-positive group included 84 (13.1%) patients. We have found statistically significant frequency of HLA-A3 (p=0.018), HLA-A66 (p=0.04), and HLA-B18 (p=0.006) antigens in PRA-positive patients and DRB1*07 (p=0.02) having the highest frequency in patients with sensitizing event history but no anti-HLA development suggesting that DRB1*07 might be associated with low risk of anti-HLA antibody formation.
authors.affiliation: Department of Medical Biology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. gonca.karahan@gmail.com
authors.forename: Gonca Emel
authors.initials: GE
authors.lastname: Karahan
authors.forename: Cigdem
authors.initials: C
authors.lastname: Kekik
authors.forename: Fatma Savran
authors.initials: FS
authors.lastname: Oguz
authors.forename: Ayse Emel
authors.initials: AE
authors.lastname: Onal
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Bakkaloğlu
authors.forename: Yaşar Kerem
authors.initials: YK
authors.lastname: Calişkan
authors.forename: Halil
authors.initials: H
authors.lastname: Yazici
authors.forename: Aydin
authors.initials: A
authors.lastname: Turkmen
authors.forename: Ali Emin
authors.initials: AE
authors.lastname: Aydin
authors.forename: Mehmet S
authors.initials: MS
authors.lastname: Sever
authors.forename: Ulug
authors.initials: U
authors.lastname: Eldegez
authors.forename: Mahmut Nezih
authors.initials: MN
authors.lastname: Carin
mesh_terms: D000328:Adult; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D010641:Phenotype
chemical_list: D006680:HLA Antigens; D007518:Isoantibodies